Cargando…
Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931933/ https://www.ncbi.nlm.nih.gov/pubmed/27382560 http://dx.doi.org/10.5045/br.2016.51.2.137 |
| _version_ | 1782440981458583552 |
|---|---|
| author | Tendas, Andrea Niscola, Pasquale Scaramucci, Laura Cupelli, Luca Perrotti, Alessio Pio de Fabritiis, Paolo |
| author_facet | Tendas, Andrea Niscola, Pasquale Scaramucci, Laura Cupelli, Luca Perrotti, Alessio Pio de Fabritiis, Paolo |
| author_sort | Tendas, Andrea |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4931933 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-49319332016-07-05 Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab Tendas, Andrea Niscola, Pasquale Scaramucci, Laura Cupelli, Luca Perrotti, Alessio Pio de Fabritiis, Paolo Blood Res Letter to the Editor Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2016-06 2016-06-23 /pmc/articles/PMC4931933/ /pubmed/27382560 http://dx.doi.org/10.5045/br.2016.51.2.137 Text en © 2016 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Tendas, Andrea Niscola, Pasquale Scaramucci, Laura Cupelli, Luca Perrotti, Alessio Pio de Fabritiis, Paolo Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab |
| title | Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab |
| title_full | Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab |
| title_fullStr | Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab |
| title_full_unstemmed | Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab |
| title_short | Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab |
| title_sort | primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931933/ https://www.ncbi.nlm.nih.gov/pubmed/27382560 http://dx.doi.org/10.5045/br.2016.51.2.137 |
| work_keys_str_mv | AT tendasandrea primaryacquiredchronicpureredcellaplasiarefractorytostandardtreatmentsremissionwithrituximab AT niscolapasquale primaryacquiredchronicpureredcellaplasiarefractorytostandardtreatmentsremissionwithrituximab AT scaramuccilaura primaryacquiredchronicpureredcellaplasiarefractorytostandardtreatmentsremissionwithrituximab AT cupelliluca primaryacquiredchronicpureredcellaplasiarefractorytostandardtreatmentsremissionwithrituximab AT perrottialessiopio primaryacquiredchronicpureredcellaplasiarefractorytostandardtreatmentsremissionwithrituximab AT defabritiispaolo primaryacquiredchronicpureredcellaplasiarefractorytostandardtreatmentsremissionwithrituximab |